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In the last few years, there has been an increased focus by
pharmaceutical companies on their sales and marketing
activities. The highly competitive environment, along with
the availability of similar competing products has made it
challenging for sales professionals to promote the prescrip-
tion of their products. Traditionally sales activities have
mainly focussed on educating physicians and pharmacists
about new products and providing the necessary informationabout usage and beneﬁts. Besides the usual marketing activ-
ities, one of the most effective ways in which pharmaceuti-
cal companies have increased prescription of their products
has been through adoption of unique selling strategies by
their sales force. The pharmaceutical industry, both in India
and globally, has had a long history of using personal selling,
and there has been a recent sizeable increase in efforts to
improve their sales organisation and strategy, considering
the complex selling environment.
The efﬁcacy of personal selling arguably, varies according
to the different industries, markets and products in ques-
tion, as well as the various customer types. In pharmaceuti-
cal selling, the sales representative provides physicians and
pharmacists with the latest information and updates on
Novo Nordisk: An introduction
3
Novo Nordisk (NN) is a leading global provider of diabetes care
products. The company has a presence in 75 countries and markets
its products in more than 180 countries. The company has a signiﬁ-
cant presence in three therapy areas – diabetes care, haemophilia and
growth hormone. A new addition to this list is obesity management.
Novo Nordisk is headquartered in Bagsvaerd, Denmark and employs
41,500+ people as of 31 December 2015.
In early 2014, Novo Nordisk launched “Cities Changing Dia-
betes”, a partnership programme to ﬁght urban diabetes. The com-
pany's rapid growth and success in India is owing to its quality
products, commitment to upholding its values and a strategic
approach towards business, which is popularly known as the NN
Way, as discussed below.
In recognition of the fact that pharma will become global, Novo
Nordisk has a set of guiding principles called Novo Nordisk Way
that underpins every decision the organisation makes. It describes
who the organisation is, how it works and what it wants to achieve,
and sets a clear direction for the company and its employees. A com-
mitment is made to each employee and to the millions of patients all
over the world who rely on the company's products to lead full and
healthy lives.
Since its inception the founders of Novo Nordisk embarked on a
journey to change the state of diabetes; today, thousands of employ-
ees across the globe are taking this journey forward. The organisa-
tion's stated ambition is to strengthen its leadership in diabetes, and
discover and develop innovative biological medicines that are acces-
sible to patients throughout the world. Novo Nordisk stresses the
importance of balancing ﬁnancial, social and environmental consid-
erations; and to never compromise on quality and business ethics.
The company culture instils openness, honesty and treating everyone
with respect, always keeping in mind what is best for patients,
employees and shareholders.
3 Retrieved from http://www.novonordisk.co.in/about-novonor
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mation is crucial for both physicians and pharmacists, since
the pharmaceutical industry is a dynamic one. The sales rep-
resentative receives feedback from the physicians about the
drug use, which is passed back to the R&D department of the
representative's company. The success of selling in the phar-
maceutical sector largely depends on the kind of relation-
ship built with physicians, pharmacists and hospital
administrators. In particular, the relationship quality and
salesperson's expertise signiﬁcantly inﬂuence physicians’
trust and decisions. In this context, our interview aims to
identify the signiﬁcance of personal selling in assisting the
decision-making process of physicians, as well as the build-
ing of long-term relationships which is crucial for the success
of pharmaceutical companies.
The Indian pharmaceutical sector
Globally, the pharmaceutical sector has been going through
unprecedented disruptions over the last decade. While the
sector has shown overall growth in India, the rate of growth
has been inconsistent (Agarwal, Dreszer and Mina, 2017).
The large pharmaceutical companies have shown a keen
interest in expanding to rural India, and along multiple verti-
cals. The pharma sector in India has also undergone signiﬁ-
cant shifts and innovations.
Companies in this sector have adopted multi-channel
sales and marketing models, and strategies to maximise the
reach of their products. The Indian pharmaceutical industry
is different from the global pharmaceutical industry.
According to reports by India Brand Equity Foundation
(IBEF) 20171, the Indian pharma sector is:
 growing at a rate of more than 10–12 % per year, com-
pared to 7% annual growth for the world market;
 expected to expand at a CAGR of 22.4%, and reach US$55
billion by 2020;
 one of the fastest-growing sectors in the country,
accounting for about 1.4% of the global pharmaceutical
industry in value terms.
 subject to increasing pressure to innovate due to a rise in
patent expirations, weak pipeline quality and increasing
focus by governments to reduce health care costs; and
 ranked ﬁfth in the world in terms of attracting foreign
direct investment (FDI), with a cumulative ﬂow of
USD11.6 billion from 2000–2014.
In the context of the Indian pharmaceutical sector, busi-
ness strategies that are appropriate in the Western context
may not be suitable in India.2 Further, we cannot contend
that the Indian pharmaceutical industry has followed the
same growth pattern as that of the Western countries in the
past.
With the rise in FDI inﬂows, there has been an increase in
the ﬂow of funds into Indian pharma, and companies are
developing their expansion plans accordingly.1 Retrieved from https://www.ibef.org/industry/pharmaceutical-
india.aspx (Accessed in September 2018).
2 https://www.mckinsey.com/industries/pharmaceuticals-and-med
ical-products/our-insights/whats-next-for-pharma-in-emerging-mar
kets last accessed in July 2017.Personal selling in the pharmaceutical Industry
Indian pharmaceutical companies have transitioned from
conservative sales models to more innovative approaches.
This expansion in recent years has led to an increase in the
number of global brands and products launched. At the same
time, the sales force has been expanding signiﬁcantly to
reach all parts of the country. In a bid to further increase
revenues, companies have started to engage in better scien-
tiﬁc promotion, and deployment of new and efﬁcient sales
force structures to more target markets.4
Pharmaceutical companies have begun to direct their
sales force at physicians who make decisions on the prescrip-
tion of drugs. Approximately 65% of the total spending of
pharmaceutical companies has been on their sales force,
which in turn provides the latest information about the drugs
and plays a major role in the decisions made by physicians as
to whether the drug should be prescribed. With the rapid
changes in the industry and new drugs continually beingdisk.html (accessed on 30 December 2016). The content in this sec-
tion is drawn heavily from Novo Nordisk company documents.
Further the content is vetted by the competent authorities from
Novo Nordisk.
4 Retrieved from https://www.imshealth.com (accessed on 30
December 2016).
6 Retrieved from http://www.pwc.com/gx/en/ceo-agenda/ceosur
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about products in the industry.
However, because physicians are under signiﬁcant pressure,
it is impossible for them to keep themselves updated on new
products on their own, so salespeople have become an impor-
tant source of information for them. The important role of
the sales representative in the new sales model makes it
imperative for every company to manage its sales force well,
so that physicians see the information provided as credible
and have conﬁdence in prescribing drugs. Since sales repre-
sentatives are the company's point of contact with physicians,
it is crucial for the organisation's success to maintain positive
buyer–seller relationships. However, sales representatives face
numerous challenges in their day-to-day selling activities.
The challenges of pharmaceutical selling
Pharma has faced signiﬁcant challenges, especially in recent
years when government regulations have begun to add to
the pressures of an extremely competitive Indian market.
Pharmaceutical selling will experience even greater com-
plexities in the near future. Some of these challenges, and
the way forward according to some industry analysts5 and
reports (Bhangale, 2008), are as follows:
Talent
 Attracting good talent for pharmaceutical selling has
been a major concern due to stereotyping and conserva-
tive payouts.
 Given the growth of sales jobs in information technology
and ﬁnancial institutions, this profession has become
less appealing to the younger generation.
Customers
 It takes nearly 6–8 months for sales representatives to
familiarise themselves with selling techniques and get
strong customer insights, but they are under pressure to
deliver on the job immediately.
 Selling channels and trade can also put tremendous pres-
sure on “ethical” standards.
Technology
 Use of information technology and gadgets such as iPads
and tablets are slowly becoming the norm as pharmaceu-
tical sales tools, and they enable the capture of real-
time data that could give sales representatives, manag-
ers and the marketing team much needed insights.
 These tools can also be used to understand prescription
preferences and trends.
Human element
 Personal selling by sales representatives is the core to
“winning” in a sales job, and technology can only help as
enablers to make the role more reﬁned and better.5 Retrieved from https://www.linkedin.com/pulse/2014-
0708104222–67802854-pharmaceutical-selling-challengesand-way-
forward (accessed on 30 December 2016). There is a need for a customer- or patient- centric
approach in designing marketing and sales activities.
 It entails more responsibility towards clients, patients
and society.
According to the PWC 19th Annual Global CEO Survey6 some
major concerns for CEOs related to selling in pharma are:
 Finding people with the right skills: CEOs struggle to ﬁnd
professionals with growth potential.
 Balancing the needs of customers and society: Pressure
from customers is a driving force, as is pressure from
regulators and governments.
 Investing in innovation: Innovation, in terms of both pro-
cess and selling approaches, is a top priority.
 Technology: Technological advances will help more than
hinder; however, there are concerns that the rate of
technological change will have a huge impact on the sell-
ing process.
 Integrity: CEOs are taking safety seriously and wish to ensure
that the integrity of their representatives is nurtured.
Novo Nordisk: Continuing the journey
In this interview, Mr Melvin D'Souza, Vice President and Gen-
eral Manager, Novo Nordisk India, explains the reasons
behind the company's phenomenal growth, and also assesses
the challenges facing the company and the industry, espe-
cially in the sales domain.
During this interaction, Mr D'Souza shares insights on Novo
Nordisk continuing its journey of change by leveraging its
strong sales force, innovative product range, and focus on
ethics and quality to engage with all key stakeholders in India.
The pharmaceutical sector is operating in a highly complex
and competitive environment and that calls for a deep under-
standing of the existing health care setup. A good understand-
ing regarding how challenges can be overcome can greatly
help others who wish to succeed in this industry.
This interview also touches upon some of the challenges in
pharmaceutical selling as detailed above. Through this inter-
view, we hope to generate interest among pharmaceutical com-
panies, as well as sales professionals, to invest in best practices
in order to remain proﬁtable and competitive.
In conversation with Mr Melvin D'Souza, Vice
President and General Manager, Novo Nordisk
India
Mr Melvin D'Souza has a rich experience of over 22 years in
the global pharmaceutical industry. He started his career as
a senior marketing executive at Novo Nordisk in India in
1995 and progressed through the ranks. He has been respon-
sible for propelling Novo Nordisk into becoming one of the
fastest-growing organisations among the top 10 pharma
MNCs in India7 by spearheading strategic interventions and
championing new sales initiatives.vey/2016.html (accessed on 30 December 2016).
7 Retrieved from https://medicinman.net/2016/10/ims-health-mar
ket-reﬂection-report-for-september-2016 (accessed in October
2016).
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tal in building a comprehensive plan for the Indian market,
with a special focus on delivering care to the remotest parts
of the country, which in turn enabled them to provide
affordable treatment to thousands. He was also involved in
forging long-lasting relationships with senior government
ofﬁcials from different state governments. This partnership
model has since been adopted by other state governments
for improving diabetes care. As the Vice President and Gen-
eral Manager of Novo Nordisk India Pvt Ltd., Mr. D'Souza is
responsible for the company's strategy and daily operations,
as well as nurturing key alliances and business partnerships.
Prior to taking over as General Manager of Novo Nordisk in
India, he was Director, Sales and Marketing for Novo Nordisk
Gulf.
Mr Melvin D'Souza holds an Executive MBA from ALBA
Graduate Business School, Athens, Greece; and a Master's in
Pharmaceutical Marketing Management from Manipal Col-
lege of Pharmaceutical Sciences, Manipal.
Sridhar Guda/ Teidorlang Lyngdoh: Mr D'Souza, thank
you for accepting our invitation. Could you please take us
through your experience at Novo Nordisk and the key lessons
learned?
Melvin D'Souza: Thank you for this opportunity. I con-
sider myself fortunate to have begun my career in a cus-
tomer-facing role despite a postgraduate degree in
marketing. This enabled me to get out of my comfort zone,
and I gave it my best shot every day by utilising every oppor-
tunity given to me.
After starting my career in sales, I was also keen to work
in marketing. However, destiny had other plans for me. In
the late 1990s, I was given an opportunity to work on an
innovative, interesting and hitherto unheard-of experiment
in the pharmaceutical industry: a direct-to-patient pro-
gramme.
With this project, Novo Nordisk was trying to get a deeper
understanding of people with diabetes. The project not only
set the bar very high for the organisation, but we were also
able to pull it off reasonably well. Though the project did
not bring in revenue, and was more long term in its outlook,
our efforts in its execution earned us due recognition. At a
later stage in my career during mainstream marketing, I was
able to replicate the best practices from this project.
Over the years, I have learned that people should step out
of their comfort zones to grab new opportunities to learn
and grow. The Indian pharmaceutical industry is full of such
opportunities. You need to be ready to embrace these, work
hard and have patience in order to reap the rewards.
Sridhar Guda/ Teidorlang Lyngdoh: Could you take us
through the performance of Novo Nordisk over the years?
Melvin D'Souza: Novo Nordisk has been in the chronic
segment for around 90 years, and that too in a single therapy
area. To my knowledge, there are not many examples of
major pharma companies that have not only survived but
also thrived by focussing on a single therapy area. As an
organisation, we help people with diabetes manage their
disorder better and live a healthy and fulﬁlling life, free of
any diabetes related complications.
We are the market leaders in India and have successfully
built several segments and product categories, in the two
decades. Our business performance has been outstanding,
with an average growth of over 20% in the past few years.We are one of the fastest-growing companies when com-
pared to the top 10 MNC pharma companies in India. We
have made a positive difference in the lives of millions of
people, and that is our inspiration.
Sridhar Guda/ Teidorlang Lyngdoh: Going by the statis-
tics, diabetes has become an epidemic in our country, while
the health infrastructure has not grown in the same propor-
tion. How is Novo Nordisk trying to navigate through these
inadequacies?
Melvin D'Souza: I agree that diabetes in India is threaten-
ing to become a health emergency and we cannot keep
blaming the system or the government. As an industry, we
should be more proactive in ﬁnding workable solutions in the
short term, and enhance awareness about diabetes by
reaching out to the masses, living in remote parts of the
country. At the same time, we should also collaborate with
the government to help them build the infrastructure over a
period. To Novo Nordisk and myself, the end result of having
a healthier and a more aware society is more important than
who is gaining more.
For the last several years, Novo Nordisk has been working
towards this outcome. We have partnered with the commu-
nity workers, with the help of state governments. We have
trained the “aanganwadi” (grassroots level health worker)
workers and local doctors, who in turn reach patients by
educating them, helping them detect diabetes and prescrib-
ing appropriate medication. We know that our journey has
just begun and there is a long way to go.
Sridhar Guda/ Teidorlang Lyngdoh: To extend this fur-
ther, how important are rural markets for Novo Nordisk?
Melvin D'Souza: In India, many people believed that dia-
betes was an urban disorder. This scenario is now changing.
The advent of the Internet and smartphones in rural India has
brought about a decisive transformation. However, public
healthcare continues to be impacted by the absence of
trained doctors. Rural markets will be the game changer for
us. Until recently, we have been able to deliver services to
tier-3 towns, as these act as feeder points for nearby villages.
We expanded our outreach in the lower tier towns with our
innovative distribution structure to capitalise on the existing
government infrastructure of Primary Health Care Centres
(PHCC) and Accredited Social Health Activists (ASHA) work-
ers. We are going to expedite the process and include many
more partners in our endeavour to achieve a healthy society.
Sridhar Guda/ Teidorlang Lyngdoh: Could you, brieﬂy,
throw some light on any such rural initiatives?
Melvin D'Souza: Our work with the Bihar government
comes to mind right away. When the government of Bihar
pledged to ﬁght diabetes through their health infrastruc-
ture, we partnered with them as the knowledge partner in
this initiative. We targeted about 100 PHCC and about 1000
anganwadi workers in 30 districts. We converted a couple of
PHCC in each district into diabetes care centres for two days
every week. Our trained staff went to the centres regularly
on these speciﬁed days, and trained PHCC staff using a
standardised programme manual. Our objective was to
make these partners efﬁcient enough to conduct the initial
diagnosis of diabetes and, if required, ask patients to visit a
specialist. The results were very encouraging – on an aver-
age, out of every 100 outpatients at a PHCC, ﬁve or six were
new patients diagnosed with diabetes who required profes-
sional help to manage their condition.
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good sales force for your organisation, and how are your pol-
icies structured to get good graduates into the sales force?
Melvin D'Souza: In India, Novo Nordisk has 80% of its
workforce in sales. At Novo Nordisk, we provide great oppor-
tunities for outstanding performers and the role in sales is
just the beginning.
Many of my peers in similar roles globally are the best exam-
ples of this; I started my career as a marketing executive in
sales and am now heading the India operations. The boundaries
of career progression at Novo Nordisk are unlimited.
Having said that, we do face challenges in getting good
graduate candidates for sales roles, but then again, we
are not alone in facing this challenge. Selling in pharma is
at the crossroads, but I feel that we are in for a better
future. First, the industry has become extremely competi-
tive, with complex products which require a deep under-
standing of the disease state, pharmaco-economics and
ability to leverage innovative tools to interact with
customers.
Secondly, ethics and customer engagement will remain a
top priority for companies. This means that we require peo-
ple who will work ethically on several new sales competen-
cies. While this may seem challenging in the short term, in
the longer run, the new pharma sales job of the future would
be more exciting, high on esteem by bringing in credibility to
the role, and great rewards for highly skilled and talented
individuals.
We are not short of a talent pool, but we need to be more
competitive vis a vis other industries. We have to build cred-
ibility around the role of a medical representative, attract
this “new” talent, and carefully nurture him/ her for the
long term.
Sridhar Guda/ Teidorlang Lyngdoh: How do you make Novo
Nordisk attractive to work for, and thus retain sales talent?
Melvin D'Souza: For some time now, sales force retention
has been an issue within the pharma industry. For us too, the
situation hasn't been much different. However, I am also
proud that our retention rates are almost 10% higher than
the industry average.
Our sales force delivers quality products to our customers
but also acts as lifesavers, with members who work towards
saving people's lives with diabetes and haemophilia. We rig-
orously train and re-train them, and expose them to technol-
ogy early in their selling lifecycle, which become core
enablers in delivering exceptional service to all our stake-
holders. Apart from this, we provide them with broader
career growth opportunities in the organisation.
We are guided by our values through the Novo Nordisk
Way – the 10 essentials that help us in how we think and
what we value. Overall, we have developed an ecosystem
that helps representatives become ﬁnancially strong, ethi-
cally and socially responsible, and work for something that
the company stands for – contributing towards a healthy
society. We believe that we have come a long way towards
making sales jobs in Novo Nordisk truly attractive to work
for.
Sridhar Guda/ Teidorlang Lyngdoh: How do you ensure
that the sales force you hire really believes in ethics, and
bases their work on Novo Nordisk values?
Melvin D'Souza: There are two things which give us
immense satisfaction but also keep us awake every night:the quality of our products we deliver and business ethics
standards we have to adhere to.
While we try to deliver the best on both counts, you need
to see these two areas on a relative scale. What was consid-
ered a good service quality or ethical standard yesterday
may not applicable today. Hence, we continue to update
ourselves in real time to retain our relevance in this dynamic
environment. We convey our values to the sales force in sev-
eral ways, including rigorous training and live examples.
We have debated extensively on these issues within the
organisation. We have now decided that some issues like
ethics and quality are non-negotiable, always. Interestingly,
as an industry, we build businesses by delivering care for an
ailment. This calls for a deeper understanding from our side
as to what we are doing and how we are doing it. Our behav-
iours to a large extent drive our actions, and actions are
what people look for in us. Our mantra is to be focussed and
sustainable. To be both, we have to be highly ethical and
quality conscious.
Sridhar Guda/ Teidorlang Lyngdoh: Novo Nordisk has
been one of the pioneers of technology use in selling, such
as using iPads instead of product brochures. Could you
explain some of these initiatives used to increase the pro-
ductivity of the sales force?
Melvin D'Souza: We are fortunate because we are a
“small–big” company – small because we are in a niche
space, and big because we are leaders in that space. So,
in this position of strength, we get a lot of opportunities
to experiment. In addition, being in India is a boon as
the world is looking to us for low-cost and sustainable
innovations. I see a future in these investments. The eco-
system and government has been spending a lot on tech-
nology and we too are quick to embrace technology,
faster than in other markets. If we are ready as an orga-
nisation to leverage technology, we can partner with our
stakeholders to offer our services and products, thus
building a healthier society.
Sridhar Guda/ Teidorlang Lyngdoh: Sales in an organisa-
tion has a lot to do with the culture. Given the diversity in
the workforce, how are you able to ensure that you create a
unique culture of your own?
Melvin D'Souza: Yes, certainly. Novo Nordisk Way of
Selling uniﬁes our selling efforts irrespective of the back-
ground of the salesperson. But this is not as easy as it
appears. India is a country in which many countries exist.
We cannot have a uniﬁed approach for every city. For
example, Chennai and Noida are similar in their physical
infrastructure, but differ socially. I require “farmers” in
some places and “hunters” in others. I have to be sure
that I do not have hunters at farming locations and
vice versa. I believe that if we want to maximise the
opportunity provided by different products and places,
we need a diversiﬁed sales force. We have to ensure
that it is part of our selection criteria, part of our
training programmes, and that is why we are very
speciﬁc about what type of people we bring in. The
bottom line is that we have a standardised approach of
selling as a guiding principle that is non-negotiable. We
are also ﬂexible on other requirements in order to
harness greater potential.
Sridhar Guda/ Teidorlang Lyngdoh: Leadership is unde-
niably the key competitive advantage in organisations like
390 S. Guda, T. Lyngdohyours. How are you nurturing the future generations to build
a good leadership pipeline?
Melvin D'Souza: You are absolutely right, and we are
building our sales organisation in this direction. Over the past
decade, we have been focussing on how to grow. We have
experimented with various models that will bring us growth.
We are aware that sustainable future growth requires organi-
sational restructuring, and we have already begun our jour-
ney towards this. We have developed a blueprint for this and
we need to continuously update our plans. We intend to build
leadership at every level of our organisation. We have
recently strengthened our support organisation, especially in
the human resource function, which is spearheading the
change process initiated. We know we have a long way to go.
Sridhar Guda/ Teidorlang Lyngdoh: How do you see Novo
Nordisk India in ﬁve years from now? Or maybe, ten years
from now?Melvin D'Souza: Novo Nordisk India can achieve signiﬁ-
cant growth in the next decade. This is irrespective of the
base volume we have. Opportunities abound in the segments
we operate in; and we are gearing up to grow. Our aim is to
make India among the top ﬁve markets for Novo Nordisk
worldwide from 2030.
Sridhar Guda/ Teidorlang Lyngdoh: Thank you, Mr
D'Souza, for your time and valuable insights into pharma
selling.References
Bhangale, Vijay (2008). Pharma marketing in India: Opportunities,
challenges and the way forward. Journal of Medical Marketing:
Device, Diagnostic and Pharmaceutical Marketing 8 (3), 205–210.
Agarwal, A., Dreszer, J. and Mina, J. (2017), “What is next for
Pharma in Emerging Markets”, URL accessed last in July 2017.
